Case reports of BRAF V600E-mutated tumors effectively treated using the agnostic approach
https://doi.org/10.18027/2224-5057-2024-14-1-92-98
Abstract
A tumor-agnostic approach to cancer treatment that implies the selection of agents targeting specific genetic aberrations and signaling pathways regardless of the tumor site of origin represents a new direction in personalized oncology. Pembrolizumab is the first therapy approved for unresectable microsatellite instability-high (MSI-H) tumors of any location. In 2022, the combination of dabrafenib and trametinib was approved by the US Food and Drug Administration (FDA) for the treatment of patients with solid tumors harboring BRAF V600E mutations. Melanomas, colorectal cancers, and non-small cell lung cancers are BRAF-mutated in 60 %, 15 %, and 5–8 % of cases, respectively. BRAF-mutated glioblastoma (3 %), cholangiocarcinoma (5–7 %), pancreatic cancer (1–16 %), and Langerhans cell histiocytosis (57 %) have also been reported.
We present two case reports of BRAF-mutated salivary gland and pancreatic cancers in patients with progressive disease despite standard-of-care therapy who were treated with a combination of dabrafenib and trametinib according to the agnostic approach.
The presented case reports have demonstrated that the agnostic approach and treatment with BRAF / MEK inhibitors stabilize the disease in patients with BRAF-positive cancers, including those with multiple metastases, and represent an additional therapeutic option for patients with rare BRAF-mutated cancers for which very few pharmacologic options are available.
About the Authors
N. V. Prokudina
Regional Clinical Hospital of the Kaliningrad Region
Russian Federation
Russian Federation
Prokudina Natalya Vladimirovna
74 Klinicheskaya str., Kaliningrad 236016
М. М. Kramchaninov
N. P. Napalkov Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Russian Federation
Kramchaninov Mikhail Mikhailovich
lit. A, 68A Leningradskaya St., Pesochnyy, Saint Petersburg 197758
References
1. El-Deiry W.S., Goldberg, R.M., Lenz H.-J., et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69(4):305–343. https://doi.org/10.3322/caac.21560
2. Kumar-Sinha C., Chinnaiyan, A.M. Precision oncology in the age of integrative genomics. Nat Biotechnol 2018;36(1):46– 60. https://doi.org/10.1038/nbt.4017
3. Yan L., Zhang W. Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun (Lond) 2018;38(1):6. https://doi.org/10.1186/s40880-018-0274-3.
4. Hyman D.M., Taylor B.S., Baselga J. Implementing Genome-Driven Oncology. Cell 2017;168(4):584–599. https://doi.org/10.1016/j.cell.2016.12.015
5. Leicht D.T., Balan V., Kaplun, A., et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007;1773(8):1196–1212. https://doi.org/10.1016/j.bbamcr.2007.05.001
6. Davies H., Bignell G.R., Coxet C., et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–954. https://doi.org/10.1038/nature00766
7. Cohn A.L., Day B.M., Abhyankar S., et al. BRAFv600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. Onco Targets Ther. 2017;10:965–971. https://doi.org/10.2147/OTT.S120440
8. Bernocchi O., Sirico M., Corona S.P., et al. Tumor type agnostic therapy carrying BRAF mutation: case reports and review of literature. Pharmaceuticals (Basel.) 2021;14(2):159. https://doi.org/10.3390/ph14020159
9. Clinical Guidelines. Malignant neoplasm of the bronchi and lung, 2022. Available at: https://cr.minzdrav.gov.ru/schema/30_4. (In Russ.)
10. Clinical Guidelines. Melanoma and mucous membranes, 2020. Available at: https://cr.minzdrav.gov.ru/schema/546_1. (In Russ.)
11. Subbiah V., Kreitman R.J., Wainberg Z.A., et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 2023;29(5):1103–1112. https://doi.org/10.1038/s41591-023-02321-8
12. Salama A.K.S., Li S., Macrae E.R., et al. Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH trial subprotocol H. J Clin Oncol 2020;38(33):3895–3904. https://doi.org/10.1200/JCO.20.00762
13. Barras D., Missiaglia E., Wirapati P., et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 2017;23(1):104–115. https://doi.org/10.1158/1078-0432.CCR-16-0140
Review
For citations:
Prokudina N.V., Kramchaninov М.М. Case reports of BRAF V600E-mutated tumors effectively treated using the agnostic approach. Malignant tumours. 2024;14(1):92-98. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-1-92-98
Views:
560
Email this article 